JP2021024790A - 光音響イメージング剤 - Google Patents
光音響イメージング剤 Download PDFInfo
- Publication number
- JP2021024790A JP2021024790A JP2019142540A JP2019142540A JP2021024790A JP 2021024790 A JP2021024790 A JP 2021024790A JP 2019142540 A JP2019142540 A JP 2019142540A JP 2019142540 A JP2019142540 A JP 2019142540A JP 2021024790 A JP2021024790 A JP 2021024790A
- Authority
- JP
- Japan
- Prior art keywords
- ring
- group
- carbon atoms
- hydrogen atom
- photoacoustic imaging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012216 imaging agent Substances 0.000 title claims abstract description 40
- 230000003287 optical effect Effects 0.000 title abstract 3
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical class [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 claims abstract description 82
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 39
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims abstract description 31
- 239000004480 active ingredient Substances 0.000 claims abstract description 20
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims abstract description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 34
- 125000001424 substituent group Chemical group 0.000 claims description 31
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 238000003384 imaging method Methods 0.000 claims description 26
- 241001465754 Metazoa Species 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 238000000862 absorption spectrum Methods 0.000 description 23
- 229960004657 indocyanine green Drugs 0.000 description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 16
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 15
- 230000031700 light absorption Effects 0.000 description 15
- 230000002378 acidificating effect Effects 0.000 description 14
- 238000010521 absorption reaction Methods 0.000 description 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 11
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 238000001834 photoacoustic spectrum Methods 0.000 description 8
- 0 CC1(C)c2c(cccc3)c3ccc2*(CCCN)=C1C=CC1=CC=C/C=C/C=C[C@]1*1CC*(Cc2ccccc2)CC1 Chemical compound CC1(C)c2c(cccc3)c3ccc2*(CCCN)=C1C=CC1=CC=C/C=C/C=C[C@]1*1CC*(Cc2ccccc2)CC1 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 125000005647 linker group Chemical group 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000006096 absorbing agent Substances 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 5
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 4
- -1 carboxyethyl group Chemical group 0.000 description 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 241000792859 Enema Species 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 125000004181 carboxyalkyl group Chemical group 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 229940095399 enema Drugs 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
- OTPDWCMLUKMQNO-UHFFFAOYSA-N 1,2,3,4-tetrahydropyrimidine Chemical group C1NCC=CN1 OTPDWCMLUKMQNO-UHFFFAOYSA-N 0.000 description 1
- DKYBVKMIZODYKL-UHFFFAOYSA-N 1,3-diazinane Chemical group C1CNCNC1 DKYBVKMIZODYKL-UHFFFAOYSA-N 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- VVLIFBHAYZFQQB-UHFFFAOYSA-N CC1(C)N(C2)C2C1 Chemical compound CC1(C)N(C2)C2C1 VVLIFBHAYZFQQB-UHFFFAOYSA-N 0.000 description 1
- RXYPXQSKLGGKOL-UHFFFAOYSA-N CN1CCN(C)CC1 Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 description 1
- ZAKHNVIDWMIMPU-UHFFFAOYSA-N CN1CCN(Cc2ccc(CC(O)=O)cc2)CC1 Chemical compound CN1CCN(Cc2ccc(CC(O)=O)cc2)CC1 ZAKHNVIDWMIMPU-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N CN1CCNCC1 Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical group C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000010895 photoacoustic effect Methods 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 230000035440 response to pH Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- PUIWPNXPCPENEL-UHFFFAOYSA-M sodium;1-[6-[2-[7-[1,1-dimethyl-3-(4-sulfonatobutyl)benzo[e]indol-2-ylidene]hepta-1,3,5-trienyl]-1,1-dimethylbenzo[e]indol-3-ium-3-yl]hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)\C1=C\C=C\C=C\C=C\C(C(C1=C2C=CC=CC2=CC=C11)(C)C)=[N+]1CCCCCC(=O)ON1C(=O)CC(S([O-])(=O)=O)C1=O PUIWPNXPCPENEL-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Indole Compounds (AREA)
Abstract
Description
[1] 下記一般式(1)
で表される構造を有する、インドシアニングリーン誘導体。
[2] 前記一般式(1)で表される構造が、下記一般式(1−1)〜(1−6)
のいずれかで表される構造である、前記[1]のインドシアニングリーン誘導体。
[3]前記一般式(1)で表される構造が、下記一般式(1−1−1)〜(1−1−3)、(1−4−1)及び(1−4−2)
のいずれかで表される構造である、前記[2]のインドシアニングリーン誘導体。
[4] 前記[1]〜[3]のいずれかのインドシアニングリーン誘導体を有効成分とする、光音響イメージング剤。
[5] 前記[1]〜[3]のいずれかのインドシアニングリーン誘導体を有効成分とする、医薬用組成物。
[6] 前記[4]の光音響イメージング剤を動物個体(ただし、ヒトを除く)に投与し、外部から近赤外光を照射し、発生した光音響波を検出して光音響イメージング画像を作製する、光音響イメージング画像の作製方法。
[7] さらに、前記動物個体に、外部から超音波を照射し、エコー画像を作製し、
前記エコー画像と前記光音響イメージング画像を重ね合わせる、前記[6]の光音響イメージング画像の作製方法。
ICG誘導体を合成し、その光吸収スペクトルを測定した。
下記の合成反応により、10種類のICG誘導体を合成した。合成したICG誘導体は、NMRとMSにより、目的の構造のICG誘導体が合成できたことを確認した。
合成したICG誘導体の光吸収特性を調べるために、ジメチルスルホキシド(DMSO)を共溶媒とした様々なpHのリン酸緩衝液(30容量%のDMSOと70容量%のリン酸緩衝液)中において、1μMの濃度で、紫外・可視分光光度計を用いて吸収スペクトルを測定し、そのpH依存性を検討した。各ICG誘導体の吸収スペクトルを図1〜10に示す。
TMEDA−CyとTMPDA−Cyについて、さらに光音響シグナルを検出し、光音響スペクトルと吸収スペクトルとの相関性を調べた。ICG誘導体を10μMとなるようにリン酸緩衝液(pH3.5又は7.0)に溶解した溶液をサンプルとし、これに、波長可変OPOレーザー(パルス幅:6〜8ns、繰り返し周波数:10Hz、パルスエネルギー:20〜50mJ)で、短パルスレーザー光を照射し、発生した光音響シグナルを測定した。励起波長は、500〜1000nmの範囲に5nm刻みで測定し、照射エネルギーは100±50μJ/パルスとした。
Claims (7)
- 請求項1〜3のいずれか一項に記載のインドシアニングリーン誘導体を有効成分とする、光音響イメージング剤。
- 請求項1〜3のいずれか一項に記載のインドシアニングリーン誘導体を有効成分とする、医薬用組成物。
- 請求項4に記載の光音響イメージング剤を動物個体(ただし、ヒトを除く)に投与し、外部から近赤外光を照射し、発生した光音響波を検出して光音響イメージング画像を作製する、光音響イメージング画像の作製方法。
- さらに、前記動物個体に、外部から超音波を照射し、エコー画像を作製し、
前記エコー画像と前記光音響イメージング画像を重ね合わせる、請求項6に記載の光音響イメージング画像の作製方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019142540A JP7312441B2 (ja) | 2019-08-01 | 2019-08-01 | 光音響イメージング剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019142540A JP7312441B2 (ja) | 2019-08-01 | 2019-08-01 | 光音響イメージング剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021024790A true JP2021024790A (ja) | 2021-02-22 |
JP7312441B2 JP7312441B2 (ja) | 2023-07-21 |
Family
ID=74663770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019142540A Active JP7312441B2 (ja) | 2019-08-01 | 2019-08-01 | 光音響イメージング剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7312441B2 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113461588A (zh) * | 2021-06-29 | 2021-10-01 | 山东省科学院海洋仪器仪表研究所 | 一种胃酸监测用荧光探针及其制备方法和应用 |
WO2022163807A1 (ja) * | 2021-01-29 | 2022-08-04 | 国立大学法人北海道大学 | 光音響イメージング剤 |
CN115837015A (zh) * | 2022-11-02 | 2023-03-24 | 常州大学 | 基于新吲哚菁绿前药的载姜黄素纳米粒及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109020955A (zh) * | 2018-08-02 | 2018-12-18 | 深圳大学 | 一种分子探针、制备方法及其应用 |
-
2019
- 2019-08-01 JP JP2019142540A patent/JP7312441B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109020955A (zh) * | 2018-08-02 | 2018-12-18 | 深圳大学 | 一种分子探针、制备方法及其应用 |
Non-Patent Citations (2)
Title |
---|
BONIFAZI, E. L. ET AL.: "Versatile Supramolecular Organogel with Outstanding Stability toward Aqueous Interfaces", ACS APPLIED MATERIALS & INTERFACES, vol. 6, no. 12, JPN6023007757, 2014, pages 8933 - 8936, ISSN: 0005000159 * |
MENENDEZ, G. O. ET AL.: "A Versatile Near-Infrared Asymmetric Tricarbocyanine for Zinc Ion Sensing in Water", PHOTOCHEMISTRY AND PHOTOBIOLOGY, vol. 89, no. 6, JPN6023007756, 2013, pages 1354 - 1361, XP055305403, ISSN: 0005000160, DOI: 10.1111/php.12160 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022163807A1 (ja) * | 2021-01-29 | 2022-08-04 | 国立大学法人北海道大学 | 光音響イメージング剤 |
CN113461588A (zh) * | 2021-06-29 | 2021-10-01 | 山东省科学院海洋仪器仪表研究所 | 一种胃酸监测用荧光探针及其制备方法和应用 |
CN115837015A (zh) * | 2022-11-02 | 2023-03-24 | 常州大学 | 基于新吲哚菁绿前药的载姜黄素纳米粒及其制备方法和应用 |
CN115837015B (zh) * | 2022-11-02 | 2024-05-28 | 常州大学 | 基于新吲哚菁绿前药的载姜黄素纳米粒及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
JP7312441B2 (ja) | 2023-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7312441B2 (ja) | 光音響イメージング剤 | |
US9248203B2 (en) | Fluorescent imaging with substituted cyanine dyes | |
US10829477B2 (en) | Activity-based probe compounds, compositions, and methods of use | |
US5672333A (en) | Delta1,6 bicyclo 4,4,0! functional dyes for contrast enhancement in optical imaging | |
JP2016521254A5 (ja) | ||
AU2020286325B2 (en) | Activity-based probe compounds, compositions, and methods of use | |
JP5500875B2 (ja) | 新規化合物、該新規化合物を用いたプローブ及び該新規化合物もしくは該プローブを用いた蛍光イメージング用造影剤 | |
US10245329B2 (en) | Composition having dye and conjugate of polyethyleneglycol and additive and contrast agent for photoacoustic imaging having the same | |
Lesniak et al. | Dual contrast agents for fluorescence and photoacoustic imaging: evaluation in a murine model of prostate cancer | |
Hübner et al. | Probing two PESIN-indocyanine-dye-conjugates: Significance of the used fluorophore | |
US5672332A (en) | Delta 1,2 bicyclo 4,4,0! functional dyes for contrast enhancement in optical imaging | |
US5723104A (en) | Monocyclic functional dyes for contrast enhancement in optical imaging | |
JP6700750B2 (ja) | 化合物、および、前記化合物を有する光学イメージング用造影剤 | |
US10172964B2 (en) | Compound or salt thereof and contrast agent for optical imaging | |
US20040092812A1 (en) | Methods and contrast agents useful in quantifying nitric oxide | |
RU2713151C1 (ru) | Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения | |
WO2022163807A1 (ja) | 光音響イメージング剤 | |
JP6711601B2 (ja) | 光音響イメージング用造影剤 | |
US20240175874A1 (en) | Fluorescent water-soluble polycationic chitosan polymers as markers for biological 3d imaging | |
JP2017002000A (ja) | 化合物又はその薬学的に受容可能な塩、及び、前記化合物又はその薬学的に受容可能な塩を有する光音響イメージング用造影剤。 | |
US20120244079A1 (en) | Traceable retinoid acid for imaging, disease prevention and therapy | |
JP2016056170A (ja) | 色素とポリエチレングリコールの結合体と添加剤とを有する組成物、及び前記組成物を有する光音響イメージング用造影剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190926 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220720 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230216 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230426 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230620 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230703 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7312441 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |